Stock Groups

Pfizer/BioNTech COVID-19 vaccine shows 90.7% efficacy in trial in children -Breaking

by Mike Robinson

[ad_1]

© Reuters. FILEPHOTO: This illustration photo taken on March 19, 2021 shows a vial labeled with Pfizer BioNTech’s coronavirus disease vaccine (COVID-19). REUTERS/Dado Ruvic/Illustration

NEW YORK (Reuters – A clinical trial with five- to 11-year olds showed that the Pfizer/BioNTech vaccine COVID-19 was effective in preventing the coronavirus. The drugmaker from the United States said Friday.

The trial involved 16 children who received the placebo, and 3 were vaccinated. Pfizer According to briefing documents sent to U.S. Food and Drug Administration, (NYSE:).

It is believed that the vaccine had a better efficacy than placebo because more than two-thirds of the children who participated in the trial (2268) were given it.

On Tuesday, outside advisors to FDA will meet to discuss whether or not to recommend approval of the vaccine by the FDA for this age group.

Disclaimer Fusion MediaThis website does not provide accurate and current data. CFDs include stocks, futures, indexes and Forex. Prices are provided not by the exchanges. Market makers provide them. Therefore, prices can be inaccurate and differ from actual market prices. These prices should not be used for trading. Fusion Media does not accept any liability for trade losses that you may incur due to the use of these data.

Fusion MediaFusion Media and anyone associated with it will not assume any responsibility for losses or damages arising from the use of this information. This includes data including charts and buy/sell signal signals. You should be aware of all the potential risks and expenses associated with trading in the financial market. It is among the most dangerous investment types.



[ad_2]